KNSA Sale Disclosure
Ragosa Mark · SEC Form 4 · Filed Nov 3, 2026
Sale
Calculated transaction value
$20.68K
Ragosa Mark Chief Financial Officer
KNSA
Transaction date
Nov 2, 2026
Public filing date
Nov 3, 2026
Filing lag
Filed 1 day later
KNSA daily price context
Close on/before transaction
$90.8
Nov 2, 2026
First close after public filing
$96.12
Nov 4, 2026
Return after filing · so far
-2.35%
Through Nov 6, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Class A Ordinary Share
- Quantity / price
- 220 shares @ $94.01
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001835458-26-000014
Filing cohort
Transactions in this filing
Showing 12 of 12
Trades
12
Issuers
1
Estimated value
$3.87M
Buys / sales
0 / 4
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $103.68K |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $0 |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $59.81K |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $145.11K |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $171.14K |
| Kiniksa Pharmaceuticals International, Plc KNSA | Sale | Nov 2, 2026 | $1.28M |
| Kiniksa Pharmaceuticals International, Plc KNSA | Sale | Nov 2, 2026 | $1.12M |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $0 |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $0 |
| Kiniksa Pharmaceuticals International, Plc KNSA | Sale | Nov 2, 2026 | $966.5K |
| Kiniksa Pharmaceuticals International, Plc KNSA Current | Sale | Nov 2, 2026 | $20.68K |
| Kiniksa Pharmaceuticals International, Plc KNSA | Exercise | Nov 2, 2026 | $0 |